A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma ILLUMINATE-204)

Trial Profile

A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma ILLUMINATE-204)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Jul 2018

At a glance

  • Drugs Tilsotolimod (Primary) ; Ipilimumab; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ILLUMINATE 204
  • Sponsors Idera Pharmaceuticals
  • Most Recent Events

    • 16 Jul 2018 dAccording to an Idera Pharmaceuticals media release, updated data will presented at the upcoming medical conferences. The company expects completion of enrollment (n=60) by end of 2018. Top-line data from this study is expected in mid 2019.
    • 05 Jun 2018 Results of pooled data from two phase1 trials (NCT03052205 and NCT02644967), were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Results evaluating the safety and efficacy of IMO-2125 in combination with ipilimumab in PD-1 inhibitor refractory melanoma, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top